Unusual presentation of primary T-cell lymphoblastic lymphoma: description of two cases by Maria R Ambrosio et al.
Ambrosio et al. Diagnostic Pathology 2014, 9:124
http://www.diagnosticpathology.org/content/9/1/124CASE REPORT Open AccessUnusual presentation of primary T-cell
lymphoblastic lymphoma: description of two cases
Maria R Ambrosio1*, Monica Onorati1,2, Bruno J Rocca1,3, Alessandro Ginori1, Giuseppe Lobello1, Guido Petracco2,
Alessandro Davide Videtta1, Franca Di Nuovo2, Rosa Santopietro4 and Stefano Lazzi4Abstract
Background: T-cell lymphoblastic lymphoma comprises approximately 85-90% of all lymphoblastic lymphomas. It
often arises as a mediastinal mass, and with bone marrow involvement. Presentation at other sites without nodal or
mediastinal localization is uncommon.
Case report: We describe clinical, histologic, immunohistochemical, and molecular features of two cases of primary
T-cell lymphoblastic lymphoma arising respectively in uterine corpus and testis. The tumors were composed by
medium to large cells, exhibiting a diffuse pattern of growth but sometimes forming indian files or pseudo-rosettes.
The neoplastic cells strongly expressed TdT and T-cell markers in both uterine corpus and testis. However, the testis
case also showed aberrant expression of B-cell markers, thus molecular biology was necessary to achieve a final
diagnosis. T-cell receptor gene rearrangement analysis identified a T-cell origin.
Conclusions: To the best of our knowledge, only one doubtful previous case of primary uterine T-cell lymphoblastic
lymphoma and no previous cases of primary testicular T-cell lymphoblastic lymphoma have been reported. Due to the
morphology of neoplastic cells, a challenging differential diagnosis with all the tumors belonging to the so-called small
round blue cell tumor category is mandatory. In ambiguous lineage cases, molecular biology may represent an
adequate tool to confirm diagnosis.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1559880973128230
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Precursor lymphoid neoplasms include acute lympho-
blastic leukemias (ALLs) and lymphoblastic lymphomas
(LBLs) of either B- or T-cell origin [1].
According to the last World Health Organization
(WHO) classification of Tumors of Haematopoietic and
Lymphoid Tissues, T-cell ALL/LBL is a neoplasm of
lymphoblasts committed to the T-cell lineage involving
bone marrow and blood (T-ALL) [2].
T-LBL comprises approximately 85-90% of all lympho-
blastic lymphomas; similarly to its leukemic counterpart,
it is most frequent in males and in late childhood, consti-
tuting only a small percentage of adult cases [3]. T-LBL* Correspondence: maradot@libero.it
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unless otherwise stated.usually presents as a mediastinal mass, and with bone
marrow localization. Skin, tonsil, liver, spleen, central ner-
vous system (CNS) and testis in males may be affected, al-
though presentation at these sites without nodal or
mediastinal involvement is uncommon [2]. The lympho-
blasts in T-ALL/LBL (small to medium-sized cells with
scant cytoplasm, convoluted or round nuclear contours,
high nuclear/cytoplasmic ratio, immature nuclear chroma-
tin with usual inconspicuous nucleoli) are morphologically
indistinguishable from those of B-ALL/LBL. The neoplas-
tic cells express terminal deoxynucleotidyl transferase
(TdT), CD34, CD99 and variable CD2, CD3, CD4, CD5,
CD7, CD8 [2].
Treatment is generally divided into three phases
employed by using different drugs: induction (dexametha-
sone, prednisone or prednisolone, vincristine, asparaginase
and/or doxorubicin), consolidation (high dose methotrexateral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion), maintenance (weekly methotrexate plus daily mercap-
topurine) [4-6]. Given that standard doses of chemotherapy
may not reach leukemia cells in brain and spinal cord, the
cells are able to find sanctuary in the CNS, especially for
cases with testicular involvement. Therefore, another im-
portant therapeutic strategy to prevent CNS relapse is
prophylaxis by intrathecal injection [1]. Unlike to ALL and
B-cell LBL, there are no clear prognostic factors that may
predict remission or survival in T-cell LBL, although it fre-
quently occurs in older patients showing high white blood
cell count, both features associated with an adverse clinical
course [1]. It has been recently demonstrated that a
treatment strategy that includes planner consolidation
with stem-cell transplantation (SCT) produces long-term
outcome in selected adult patients [4,6]. The main differen-
tial diagnoses of LBL include Burkitt lymphoma (BL), dif-
fuse large-B cells lymphoma (DLBCL), blastic variant of
mantle cell lymphoma (MCL), small lymphocytic lymph-
oma, B1 thymoma, acute myeloid leukaemia, myeloid sar-
coma, small round blue cell tumors (including Ewing
sarcoma-ES/peripheral neuroectodermal tumour-PNET,
neuroblastoma, embryonal rhabdomyosarcoma, medullo-
blastoma) [1,6,7].
We describe two cases of primary T-LBL arising in
atypical sites, respectively uterine corpus and testis. The
importance of differential diagnosis with other lymphoid
and non lymphoid neoplasms is underlined.
Cases presentation
Case 1
A 64 years-old female was admitted to Siena University
Hospital for persistent vaginal bleeding. Physical examin-
ation revealed marked enlargement of the uterus, and ab-
dominal ultrasonography showed a 6.0x4.0 cm hypoechoic
mass in uterine corpus. Endometrial biopsy was performed.
The surgical specimen consisted of three brownish frag-
ments ranging from 0,2 to 0,7 cm in maximum diameter.
Histological examination of the formalin fixed paraffin-
embedded sections showed a polypoid lesion with atrophic
endometrium. On this background, a diffuse proliferation of
round blue cells infiltrating endometrial glands and stroma,
and dissecting the muscle fibres was observed (Figure 1A).
Cells were medium to large and exhibit a diffuse pattern of
growth sometimes forming indian files or pseudo-rosettes
(Figure 1B). A vaguely starry-sky appearance was also
present. Cytologically, some cells showed scant cytoplasm,
dense nuclear chromatin and multiple inconspicuous nucle-
oli, whereas other demonstrated prominent nucleoli. There
were numerous mitotic figures. Neoplastic cells were posi-
tive for TdT (Figure 1C), CD2 (Figure 1D), CD7, CD3,
CD10. Proliferative index (Ki-67) was high (about 90%). Mo-
lecular studies evidenced a clonal T-cell receptor (TCR)
gene rearrangement. Diagnosis of T-LBL was made.The patient underwent bone marrow biopsy with nega-
tive results and complete staging evaluation with whole
body computed tomography (CT)-scan revealed that the
disease was limited to the uterine corpus.
Treatment with systemic cyclophosphamide, vincristine
sulfate, adryamicin, dexamethasone (hyper-CVAD) proto-
col together with intrathecal chemotherapy started. The
patient died after eighteen months follow-up for a pul-
monary infection.
Case 2
A 38-year-old male presented to Garbagnate Milanese
Hospital for a sudden unilateral enlargement of the scro-
tum. His past medical history was unremarkable. On
physical examination, a painful solid mass of the left testis
was observed. The ultrasound sonography showed a
highly vascularized, hypoechoic lesion, completely infil-
trating the testis. The clinical diagnosis was testicular neo-
plasm and a total orchiectomy was performed.
On gross examination, a complete replacement of the
testis by a fleshy, whitish, homogenous mass infiltrating
the para-testicular tissues was observed. Microscopic-
ally, an extensive infiltrate of blue uniform cells between
and displacing seminiferous tubules was noted. The
neoplastic cells presented an interstitial pattern of
growth, surrounding and focally infiltrating the lining
epithelium of seminiferous tubules (Figure 2A-B). High
endothelial venules were also observed. The neoplastic
population typically grew in indian file (Figure 2B
arrow) and showed a lymphoid appearance with mor-
phologic features of a precursor lymphoma. They con-
sisted of small to medium sized cells with round to oval
nuclei, sometimes convoluted, with dispersed nuclear
chromatin, inconspicuous nucleoli, and scanty, faintly
basophilic cytoplasm. Mitoses were frequent. The neo-
plastic population expressed TdT (Figure 2C), and both
T- (Figure 2D) and B-cell markers. The proliferative
index (Ki-67) was high (about 95%). As the lineage was
ambiguous due to the positivity to CD2, CD7, Pax-5
and CD79a, molecular biology was carried out, showing
a clonal rearrangement of the gamma TCR gene.
Bone marrow biopsy was negative, whole body CT-scan
showed neither lymphoadenopathies nor mediastinal
mass, thus a diagnosis of primary T-LBL was made. The
patient was treated with hyper-CVAD protocol associated
to systemic and intrathecal injection of drugs plus high-
dose cytarabine and methotrexate. At the last follow-up
(27 months after the diagnosis) the patient is alive and
under consolidation therapy.
Discussion
In the last WHO classification, T-cell LBL is considered
an immature malignancy, thought to be the nodal/extra-
nodal presentation of ALL [1,2]. Most patients are
Figure 1 Histological and immunohistochemical features of uterine T-cell lymphoblastic lymphoma. A diffuse proliferation of round blue
cells infiltrating endometrial glands and stroma and dissecting the muscle fiber is observed (A). Cells exhibit a blastic appearance (B). They are
positive for TdT (C) and CD2 (D). [A-B: haematoxylin and eosin (H & E), C: TdT stain, D: CD2 stain; A, C-D: original magnification (O.M.), 20×, B:
O.M., 40×].
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mass and bone marrow localization [8-10]. Although
rarely, the tumor may involve lymph nodes and extra-
nodal sites (spleen, liver, testis and CNS) [2]. However, its
occurrence as a primary tumor of the reproductive system
is uncommon and rarely described in literature [11-14].Figure 2 Histological and immunohistochemical findings in T-cell lym
a proliferation of blue uniform cells with an interstitial pattern of growth, o
population expresses TdT (C) and CD2 (D) (A-B: H & E, C: TdT stain, D: CD2The peculiarities of our cases are multiple: the site of
presentation (uterus and testis), the absence of bone mar-
row involvement, the age of the patients (64 and 38 years
respectively), the ambiguous lineage of the neoplastic cells
at immunohistochemistry in one case. In addition, none of
our patients developed a leukemic disease at the lastphoblastic lymphoma of the testis. The tubules are separated by
ccasionally invading the lining epithelium (A-B). The neoplastic
stain; A: O.M., 5×; B, D: O.M., 20×; C: O.M., 40×).
Table 1 Differential diagnosis of uterine and testicular T-cell lymphoblastic lymphoma
Neoplasm Clinical features Morphology Immunophenotype Molecular features
B-LBL median age 20 years,
M > F, 90% of cases
present as B-ALL
convoluted or round nuclear contours;
immature blastic chromatin; numerous
mitotic figures
CD19 +, PAX-5 +, CD20 +/−,
TdT +, CD10 +/−, CD79 + (in 10%
of cases), T-cell antigens -
monoclonal IgH gene rearrangement; t
(9; 22) (q34; q11.2); t (12;21) (p13; q22); t
(v; 11q23); t (1; 19) (q23; p13.3);
t (5; 14) (q31; 32)
BL childhood; head and
neck and ileocecal region
frequently involved
prominent “starry sky” pattern; monotonous,
medium-sized cells with 2–5 prominent nucleoli
and distinct cytoplasmic rim; very high mitotic
and apoptotic rates
CD10 +, CD19 +, CD20 +,
CD79a +, Bcl2 -, Bcl6 +, TdT -,
Ki-67 > 99%, T-cell antigens -
monoclonal IgH gene rearrangement; t
(8; 14) (q24; q32) or t (2; 8) (p11; q24)
or t (8; 22) (q24; q11) involving MYC
DLBCL adult; frequent nodal
involvement
large or medium-sized cells with
prominent nucleoli; centroblastic or
immunoblastic appearance
CD19+, CD20+, CD79a+, PAX-5+,
CD10 +/−, Bcl6 +/−, IRF4/MUM1 +/−,
Bcl2 +/−, TdT -, T-cell antigens -
t (14; 18) (q32; q21); Bcl6
(3q27) rearrangement;
MYC (8q24) rearrangement
Myeloid sarcoma median age; frequent
history of previous or concomitant
AML, MDS, MPN, MDS/MPN
myelocytes with more distinct and
eosinophilic cytoplasm
CD43 +, CD68PGM1 +,
CD68 +, CD117 +, MPO +,
CD10 -, T-cell antigens -
no evidence of monoclonal
TCR gene rearrangements,
monosomy 7, trisomy 8
Blastoid variant
of MCL
median age 68 years, male
predominance; frequent
extranodal involvement
lymphoblastoid cells with immature
chromatin and high mitotic rate
CD19 +, CD20 +, Cyclin-D1 +, CD5 +,
CD10 -, TdT -, CD2 -, CD3 -, CD7 -
monoclonal IgH gene rearrangement;
no evidence of monoclonal TCR gene
rearrangements; t (11; 14) (q13; q32)
ES/PNET median age <20 years, M >
F; frequent bone involvement
cohesive growth pattern, frequently
pseudorosettes formation; small
blue monomorphic round cells with
fine nuclear chromatin, round
nuclei and scanty clear cytoplasm
CD99 +, vimentin +, WT-1 +,
lymphoid markers -
no evidence of monoclonal TCR gene
rearrangement; t (11; 22) (q24; q12) or
t (21; 22) (q22; q12) or t (1; 16) (q11; q11)
Alveolar
rhabdomyosarcoma
adolescents and young adults;
extremities and paraspinal
region frequently involved
nests of round cells separated
by fibrous septa, with some giant
cells and occasional clear cells
vimentin, desmin, smooth muscle actin,
HHF-35, MyoD1, myogenin +,
cytokeratins +/−, S100 +/−, CD20 +/−,
T-cell antigens -, TdT-





small ovoid, round to spindled cells with
markedly increased nuclear-to-cytoplasmic ratio,
hypercromatic nuclei and inconspicuous nucleoli
low molecular weight keratins +,
chromogranin +/−, synaptophysin +/−,
CD3 -, CD5 -, TdT -
Seminoma young adults; testicular
enlargement and hydrocele
round, polygonal cells with large and vesicular nuclei,
prominent nucleoli, clear and eosinophilic cytoplasm
and frequent mitoses, lymphoid infiltrate in the
backgournd
CD117 +, D2-40 +, OCT4 +, SALL4 +,
cytokeratins -, CD30 -, EMA -,
T-cell antigens -, TdT -
B-LBL: B lymphoblastic lymphoma; BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; AML: acute myeloid leukemia, MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; MDS/MPN: myelodysplastic/
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http://www.diagnosticpathology.org/content/9/1/124follow-up (18 months in the first case and 27 months in
the second case).
The criteria to assess the primitivity of a LBL establish
that diagnosis is correct only if the disease is confined to
the organ and no signs of leukemia are present at diagno-
sis or develop during follow-up [15,16]. Therefore, our
cases may be considered as primary T-LBL. To the best of
our knowledge, only one previous case of T-LBL of the
uterus was described in the literature, occurring in a
25 years old female [11]. However, the lack of a complete
immunohistochemical study of the case, as well as of bone
marrow biopsy and CT-scan, renders diagnosis not con-
firmed. As far as primary testicular T-LBL is concerned,
no previous case has been reported.
Due to the morphology of neoplastic cells (small to
medium-sized blast cells with scant cytoplasm, moderately
condensed to dispersed nuclear chromatin and indistinct
nucleoli to larger blasts with finely dispersed nuclear chro-
matin and relatively prominent nucleoli), differential diag-
nosis include both lymphoid and non lymphoid neoplasm,
as BL, DLBCL, blastoid variant of MCL, small lymphocytic
lymphoma, B1 thymoma, myeloid sarcoma, small cell car-
cinoma, ES/PNET, rhabdomyosarcoma, seminoma, Merkel
cell carcinoma [1,6,7]. A challenging differential diagno-
sis, especially in younger patients, is with all the tumors
belonging to the so-called small round blue cell tumor
category [1,2,6,7]. The age of the patient, the clinical
presentation, a careful morphologic examination and, fi-
nally, immunophenotyping generally permit distinction
among these diagnostic entities. In the uterine case, the
differential diagnosis among DLBCL, BL, myeloid sar-
coma, blastoid variant of MCL, small lymphocytic lymph-
oma, small (oat) cell carcinoma, rhabdomyosarcoma and
PNET was proposed (Table 1). However, an immunohisto-
chemical panel including lymphoid, myeloid, epithelial
and mesenchimal markers, ruled out any doubts. In the
testicular case, the differential diagnosis among seminoma,
BL, DLBCL, myeloid sarcoma, PNET, neuroblastoma, and
embryonal rhabdomyosarcoma was made (Table 1). Also
in this case, immunohistochemistry was helpful in achiev-
ing diagnosis. However, the ambiguous lineage of neoplas-
tic cells induced us to perform TCR and immunoglobulin
heavy chain gene (IgH) rearrangement to confirm the final
diagnosis. It is noteworthy that patients with T-cell LBL
often do express antigens more commonly associated with
other lineages, including B-cell associated antigens CD10,
CD20 and CD79a [6] as a consequence of an initial onco-
genic hit affecting the hematopoietic stem cell or a com-
mon lymphoid precursor element. Therefore, in a minority
of cases, lineage assignment on the basis of immunopheno-
type still remains unclear despite the application of a suit-
able panel of markers, thus molecular biology analysis is
necessary. Although, Pax-5 completely arrests T-cell devel-
opment, its expression has been reported in some matureT-cell lymphomas but not in T-cell LBL [17]. Nonetheless,
experimental evidence have shown that aberrant Pax-5
expression in thymocytes drives malignant transformation
[18]. These findings suggest that Pax-5 may play a role in
T-cell lymphomagenesis, including T-LBL.
Once diagnosis of T-LBL has been confirmed, a complete
staging is required to exclude bone marrow or other organ
involvement, as in our cases. T-LBL is a clinically aggressive
disease with a high risk of induction failure, frequent re-
lapse and poor survival [1]. Accordingly, high dose com-
bined systemic and intrathechal chemotherapy, followed by
intensive consolidation treatment, improves prognosis, es-
pecially in young adults [5]. Hematopoietic SCT produces
favorable long-term outcome in selected adult patients [4].
Our patients were both treated by the hyper-CVAD
protocol associated to intrathecal prophylaxys. The fe-
male patients did not underwent treatment with high-
dose cytarabine and methotrexate as it has been yielded
no clear benefits in older patients [3]. Only the patient
with testicular lymphoma is alive at the last follow-up,
perhaps for his younger age.
Conclusions
We reported two patients (ageing respectively 64 and
38 years) with T-LBL presenting as an uterine and tes-
ticular mass. Only one doubtful previous case of primary
uterine T-LBL and no previous cases of primary testicu-
lar T-LBL have been described so far. Although the fre-
quency of this type of lymphoma at these sites is very
low, primary T-LBL lymphoma still needs to be consid-
ered in the differential diagnosis of diffuse small blue cells
proliferation. Molecular biology may represent an ad-
equate tool to confirm diagnosis in ambiguous lineage
cases. Unfortunately, no clear prognostic factors that may
predict remission or survival are well established for T-
LBL [1]. Minimal residual disease detection is one of the
strongest predictors of relapse risk [6]; however, identifica-
tion of other clinical, biological and radiological parame-
ters is critical for risk stratification, especially in adult
patients, to select those who may benefit of SCT [1].
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